Fadi Joudi, MD
Urology · Wichita, KSNPI 1427050079
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2023 at $3,309 and has fallen 75.5% since, to $811 in 2025.
Across 254 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medivation LLC.$2K
- Pfizer$1K
- Daiichi Sankyo Inc.$1K
- Bayer$989
- Johnson & Johnson$668
- Axonics, Inc.$579
- plus $5K from 43 others
Across 493 payments — averaging $4596.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medivation LLC.$1.2M
- Pfizer$868K
- Dendreon Pharmaceuticals LLC$177K
- Urogen Pharma, Inc.$38K
- Sumitomo Pharma America, Inc.$21K
What the payments were for
- Consulting fees$4,09834%
- Speaking & faculty fees$1,1109%
- Food & beverage$6,43554%
- Education$3353%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$2,100
- TALZENNA$1,110
- Enhertu$1,074
- Nubeqa$924
- ANKTIVA$243
- Bulkamid$183
- Axonics$183
- UroLift$156
- JELMYTO$142
- PROVENGE$141
- Coloplast TFL Drive$137
- Nanoknife$134
- ADSTILADRIN$129
- Optilume BPH Drug Coated Balloon Catheter$112
- AMS$112
- Da Vinci Surgical System$100
How this compares
$11,978 in reported general payments places this provider in the 85th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 70 | $1,024,481 |
| XtandiEnzalutamide | 58 | $822,050 |
| NubeqaDarolutamide | 49 | $646,248 |
| OrgovyxRelugolix | 193 | $510,188 |
| GemtesaVibegron | 249 | $132,446 |
| Abiraterone Acetate | 36 | $86,127 |
| MyrbetriqMirabegron | 125 | $66,822 |
| Solifenacin Succinate | 301 | $11,469 |
| Tamsulosin Hcl | 787 | $7,442 |
| Potassium Citrate ErPotassium Citrate | 33 | $2,947 |
| Finasteride | 281 | $2,448 |
| Cephalexin | 388 | $1,995 |
| Estradiol | 26 | $1,991 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 20 | $1,892 |
| Methenamine Hippurate | 41 | $1,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $668 | $1,024,48170 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $317 | $888,871183 claims |
| BayerNubeqa | $989 | $646,24849 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $43 | $642,633442 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $97 | $86,12736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 urology providers in Kansas.
Other urology in Wichita
- Timothy RichardsonWichita$493K
- Gregory ByrdWichita$18K
- Philippe NabboutWichita$13K
- Ayham FarhaWichita$8K
- Jeffrey DavisWichita$8K
- James GilbaughWichita$5K
- Jonathan JensenWichita$4K
- George ZakhariaWichita$3K
- Surendra KollaWichita$3K
- Kahlil SaadWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.